{
    "2018-04-11": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada",
                "features": {
                    "keywords": [
                        "Rebinyn",
                        "long-acting",
                        "hemophilia B",
                        "Canada"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Novo Nordisk announces the availability of Zonovate® for the treatment of patients with hemophilia A in Quebec",
                "features": {
                    "keywords": [
                        "Zonovate",
                        "hemophilia A",
                        "Quebec"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}